<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238639</url>
  </required_header>
  <id_info>
    <org_study_id>SLICE 1</org_study_id>
    <nct_id>NCT02238639</nct_id>
  </id_info>
  <brief_title>Pulmonary Embolism as a Cause of COPD Exacerbations</brief_title>
  <acronym>SLICE</acronym>
  <official_title>Efficacy and Safety of an Active Strategy for the Diagnosis and Treatment of Acute Pulmonary Embolism (PE) in Patients With Unexplained Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Chest Physicians</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate the clinical benefits of an active strategy for the
      diagnosis and treatment of PE compared to usual care in patients with unexplained
      exacerbations of COPD who require hospital admission.

      The secondary objective is to assess the safety of an active strategy for the diagnosis and
      treatment of PE compared to usual care in patients with unexplained exacerbations of COPD who
      require hospital admission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality, symptomatic venous thromboembolism recurrence, or need for readmission.</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Clinical composite endpoint of all-cause mortality, or symptomatic venous thromboembolism recurrence, or need for readmission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>All-cause mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic recurrent venous thromboembolism</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Symptomatic venous thromboembolic recurrence confirmed by objective testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Need for readmission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Major bleeding (defined according to previously published criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non major bleeding</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Clinically relevant non major bleeding (defined according to previously published criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>90-day follow-up</time_frame>
    <description>Serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Active search for pulmonary embolism</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All included patients will undergo D-dimer testing. A negative plasma highly sensitive D-dimer value (defined as a D-dimer level below the manufacturers assay threshold) will rule out pulmonary embolism, and no further examination will be performed. For patients with a positive D-dimer value, a multidetector computed tomographic pulmonary angiography (MDCT) will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All included patients will undergo standard clinical management of their exacerbations, as deemed appropriate by the attending physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).</intervention_name>
    <description>If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.
If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation.</description>
    <arm_group_label>Active search for pulmonary embolism</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmation of COPD according to SEPAR-ALT criteria: post-bronchodilator forced
             expiratory volume in one second (FEV1)/forced vital capacity (FVC) &lt; 0.7;

          -  Hospital admission because COPD exacerbation without initial clinical suspicion of PE
             in the Emergency Department (according by the Emergency Department physician
             evaluation).

        Exclusion Criteria:

          -  Contraindication to multidetector computed tomographic angiography (allergy to
             intravenous contrast medium, or renal failure defined as a creatinine clearance less
             than 30 mL/min, according to the Cockcroft-Gault formula)

          -  Informed consent denied

          -  Pregnancy

          -  Life expectancy less than 3 months

          -  Anticoagulant therapy at the time of hospital admission

          -  Diagnosis of pneumothorax, or pneumonia (fever, and purulent sputum, and new
             infiltrate in chest X-ray)

          -  Diagnosis of lower respiratory tract infection (fever [&gt;37.8ºC], increased sputum
             volume and/or increased sputum purulence).

          -  Indication of invasive mechanical ventilation at the time of hospital admission;

          -  Impossibility for follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jimenez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>IRYCIS, Alcala de Henares University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvar Agusti, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Monreal, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Remedios Otero, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Virgen del Rocio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Jimenez, MD, PhD</last_name>
    <phone>+34669461858</phone>
    <email>djc_69_98@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Monreal, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Monreal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao</name>
      <address>
        <city>Baracaldo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aitor Ballaz</last_name>
    </contact>
    <investigator>
      <last_name>Aitor Ballaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Nostra Senyora del Remei</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federico Pablo Gomez</last_name>
    </contact>
    <investigator>
      <last_name>Federico Pablo Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Capio Sagrat Cor</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Aisa</last_name>
    </contact>
    <investigator>
      <last_name>Diego Aisa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Uresandi</last_name>
    </contact>
    <investigator>
      <last_name>Fernando Uresandi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Coruña</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Jorge Marcos</last_name>
    </contact>
    <investigator>
      <last_name>Pedro Jorge Marcos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro</name>
      <address>
        <city>Logroño</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Barron</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Barron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal, IRYCIS, Alcala de Henares University</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Jimenez, MD, PhD</last_name>
      <phone>+34913368133</phone>
      <email>djc_69_98@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>David Jimenez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dita Kopecna, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jesus Rodriguez-Nieto</last_name>
    </contact>
    <investigator>
      <last_name>Maria Jesus Rodriguez Nieto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Alcorcon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Izquierdo</last_name>
    </contact>
    <investigator>
      <last_name>Mercedes Izquierdo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ascension Hernando</last_name>
    </contact>
    <investigator>
      <last_name>Ascension Hernando</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Ignacio De Granda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier De Miguel</last_name>
    </contact>
    <investigator>
      <last_name>Javier De Miguel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Emilio Martinez-Verdasco</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Emilio Martinez-Verdasco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Baloira</last_name>
    </contact>
    <investigator>
      <last_name>Adolfo Baloira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Aguero</last_name>
    </contact>
    <investigator>
      <last_name>Ramon Aguero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico La Rosaleda</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andres Vilas</last_name>
    </contact>
    <investigator>
      <last_name>Andres Vilas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Jara</last_name>
    </contact>
    <investigator>
      <last_name>Luis Jara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Lobo</last_name>
    </contact>
    <investigator>
      <last_name>Jose Luis Lobo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Conget</last_name>
    </contact>
    <investigator>
      <last_name>Francisco Conget</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, Jardim J, López Varela V, Monsó E, Montemayor T, Viejo JL. [Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT)]. Arch Bronconeumol. 2008 May;44(5):271-81. Spanish.</citation>
    <PMID>18448019</PMID>
  </reference>
  <reference>
    <citation>Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. Epub 2007 May 16. Review.</citation>
    <PMID>17507545</PMID>
  </reference>
  <reference>
    <citation>Camargo CA Jr, Roberts J, Clark S. US emergency department visits for COPD exacerbations between 1992 and 1998. Am J Epidemiol 2001; 153: S80.</citation>
  </reference>
  <reference>
    <citation>Poulsen SH, Noer I, Møller JE, Knudsen TE, Frandsen JL. Clinical outcome of patients with suspected pulmonary embolism. A follow-up study of 588 consecutive patients. J Intern Med. 2001 Aug;250(2):137-43.</citation>
    <PMID>11489063</PMID>
  </reference>
  <reference>
    <citation>Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, Tonnel AB, Remy-Jardin M. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006 Mar 21;144(6):390-6.</citation>
    <PMID>16549851</PMID>
  </reference>
  <reference>
    <citation>Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009 Mar;135(3):786-793. doi: 10.1378/chest.08-1516. Epub 2008 Sep 23. Review.</citation>
    <PMID>18812453</PMID>
  </reference>
  <reference>
    <citation>Anderson DR, Kahn SR, Rodger MA, Kovacs MJ, Morris T, Hirsch A, Lang E, Stiell I, Kovacs G, Dreyer J, Dennie C, Cartier Y, Barnes D, Burton E, Pleasance S, Skedgel C, O'Rouke K, Wells PS. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007 Dec 19;298(23):2743-53. doi: 10.1001/jama.298.23.2743.</citation>
    <PMID>18165667</PMID>
  </reference>
  <reference>
    <citation>Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Erratum in: Chest. 2012 Dec;142(6):1698-1704.</citation>
    <PMID>22315268</PMID>
  </reference>
  <reference>
    <citation>Pozo-Rodríguez F, López-Campos JL, Alvarez-Martínez CJ, Castro-Acosta A, Agüero R, Hueto J, Hernández-Hernández J, Barrón M, Abraira V, Forte A, Sanchez Nieto JM, Lopez-Gabaldón E, Cosío BG, Agustí A; AUDIPOC Study Group. Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study. PLoS One. 2012;7(7):e42156. Epub 2012 Jul 31.</citation>
    <PMID>22911875</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health, Spain</investigator_affiliation>
    <investigator_full_name>David Jimenez</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>COPD exacerbations</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

